/Investor DB

Oxford Science Enterprises — 2022 Investments

4 investments dated 2022 · listed companies and verified rows first · show all

Bibli Ubibliu.comin𝕏Series B · Jun 2022 · $15M

BibliU is a digital learning platform that partners with publishers to provide students affordable, instant access to course content, and offers institutions workflow automation to reduce administrative burden.

EdTechSaaS

Dave Sherwood(CEO & Co-Founder)in

Co-investorsBrick Capital VenturesGreen Shores CapitalGuinness VenturesKreos CapitalOxford Investment Opportunity NetworkOxford Investment Opportunity Network (OION)+7 more

Nucleome Therapeuticsnucleome.comOct 2022

Nucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets.

AI & Machine LearningBiotechDeep Tech

Co-investorsM VenturesPfizer Venture InvestmentsBritish Patient CapitalJJDCPfizer Ventures

ONIoni.bioin𝕏Jan 2022 · $75M

ONI develops the Nanoimager, an automated super-resolution imaging system.

BiotechDeep TechHardwareMedical DevicesOxford, GB

Paul Scagnetti(Chief Executive Officer)in

Co-investorsAnjostARCH Venture PartnersArtis VenturesFuture Planet CapitalOxford Technology ManagementVertical Venture Partners+6 more

PQShieldpqshield.comin𝕏Jan 2022 · $20M

PQShield develops post-quantum cryptography (PQC) products, including optimized software libraries, SDKs, OpenSSL integration layers, and lattice-based hardware IP cores, to help organizations migrate systems to quantum-resistant cryptography.

CybersecurityDeep TechQuantum ComputingSemiconductors

Co-investorsBY Venture PartnersCrane Venture PartnersKindred CapitalAdditionChevron Technology Ventures

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.